Rilzabrutinib Granted FDA Fast Track Designation for Treatment of Immune Thrombocytopenia

PARIS– November 18, 2020 – The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the oral investigational Bruton’s tyrosine kinase (BTK) inhibitor, rilzabrutinib, which has the potential to...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials